AMLX
Amylyx Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -0.6% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 79 | +11 | 60.68M | $1.09B | +14 | −2 |
| Q1 2026 | 70 | -3 | 62.54M | $868.96M | +6 | −9 |
| Q4 2025 | 73 | 0 | 62.47M | $754.72M | — | — |
| Q3 2025 | 18 | +1 | 42.12M | $572.37M | +1 | — |
| Q2 2025 | 14 | -1 | 33.34M | $213.68M | — | −1 |
| Q1 2025 | 12 | +1 | 15.66M | $55.46M | +2 | −1 |
| Q4 2024 | 11 | 0 | 5.41M | $20.47M | +1 | −1 |
| Q3 2024 | 10 | +2 | 5.23M | $16.93M | +2 | — |
| Q2 2024 | 8 | — | 10.16M | $19.31M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 1.97M | +3.8% | $7.45M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 1.97M | +3.8% | $7.45M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Two Sigma Investments ✦ | 651.52K | +77.4% | $2.46M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Millennium Management ✦ | 594.24K | +30.1% | $2.25M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 567.90K | +3.1% | $2.15M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 567.90K | +3.1% | $2.15M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 464.40K | +70.9% | $1.76M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 306.74K | -55.6% | $1.16M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 306.74K | -55.6% | $1.16M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | State Street Global Advisors ✦ (passive) | 218.38K | — | $825,488 | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 209.71K | New | $792,697 | 0.0% | New | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 209.71K | New | $792,697 | 0.0% | New | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 188.39K | -71.0% | $712,099 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | Marshall Wace ✦ | 184.68K | -35.0% | $698,083 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Marshall Wace ✦ | 184.68K | -35.0% | $698,083 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 57.70K | +3.8% | $219,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Wellington Management | $792,697 | 0.0% |
| Wellington Management | $792,697 | 0.0% |
Exited
| Point72 Asset Management | $648 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 170 holders, 113.99M shares, $1.58B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.